Title:
USE OF RBM46 AS MARKER OF TRIPLE-NEGATIVE BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2021/000667
Kind Code:
A1
Abstract:
Disclosed is the use of a quantitative detection reagent of an Rbm46 mRNA or protein in preparing a reagent or kit for the diagnosis and/or prognosis evaluation of triple-negative breast cancer.
Inventors:
LIU NIAN (CN)
Application Number:
PCT/CN2020/092586
Publication Date:
January 07, 2021
Filing Date:
May 27, 2020
Export Citation:
Assignee:
BEIJING TAIDONG BIOTECHNOLOGY CO LTD (CN)
International Classes:
C12Q1/6886; C12N15/11; G01N33/574
Domestic Patent References:
| WO2017203526A1 | 2017-11-30 |
Foreign References:
| CN110241216A | 2019-09-17 |
Other References:
RAGHAVENDRA A. ET AL.: "Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers", HISTOPATHOLOGY, vol. 73, no. 1,, 14 April 2018 (2018-04-14), XP055771398, DOI: 20200826062447X
GRIGORLADLS A. ET AL.: "CT-X antigen expression in human breast cancer", PNAS, vol. 106, no. 32, 11 August 2009 (2009-08-11), XP055102095, DOI: 20200826062543X
CURIGLIANO G. ET AL.: "Cancer-testis antigen expression in triple-negative breast cancer", ANNALS OF ONCOLOGY, vol. 22, no. 1,, 7 July 2010 (2010-07-07), XP055771394, DOI: 20200826063038X
GRIGORLADLS A. ET AL.: "CT-X antigen expression in human breast cancer", PNAS, vol. 106, no. 32, 11 August 2009 (2009-08-11), XP055102095, DOI: 20200826062543X
CURIGLIANO G. ET AL.: "Cancer-testis antigen expression in triple-negative breast cancer", ANNALS OF ONCOLOGY, vol. 22, no. 1,, 7 July 2010 (2010-07-07), XP055771394, DOI: 20200826063038X
Attorney, Agent or Firm:
CHOFN INTELLECTUAL PROPERTY (CN)
Download PDF: